Formulary Chapter 14: Immunological products and vaccines - Full Chapter
|
14.05.02 |
Disease-specific immunoglobulins |
|
|
Varicella-Zoster immunoglobulin (VZIG)
|
Formulary
|
Varicella-zoster immunoglobulin (VZIG) prophylaxis is recommended for individuals who fulfil all of the following three criteria: - Significant exposure to chickenpox (varicella) or shingles (zoster) during the infectious period,
- At increased risk of severe chickenpox i.e. immunosuppressed individuals, neonates and pregnant women,
- No antibodies to varicella-zoster virus (VZV). Urgent VZV antibody testing can be performed within 24 hours.
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Red: Medicines which should only be prescribed in secondary care by a specialist. |

|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |

|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |

|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |

|
Brown: Medicines which should only be prescribed in restricted circumstances. |

|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |

|
not used |
|
|